Olympus Scope Litigation Status: November 2026 Update
This page tracks where the Olympus scope infection litigation stands. It is reviewed monthly, and the sections below show what we checked and when. It is general information, not legal advice, and statements about lawsuits describe allegations, not court findings.
Where things stand on November 9, 2026
The litigation has three tracks that are easy to confuse: individual lawsuits in court, FDA enforcement against Olympus, and Olympus’s own disclosures. They are related but separate, and a development in one does not decide the others.
The courts
Patients are filing individual product liability lawsuits in state and federal courts. We have found no report of a pending request to consolidate them into a multidistrict litigation, in which federal cases are coordinated before one judge. The Judicial Panel on Multidistrict Litigation keeps the official list of pending requests, and we could not view its current version, so it is the place to confirm.
One example of a recent filing is a federal wrongful death complaint filed on June 5, 2026 in the Western District of Washington. It alleges that a patient developed a fatal vancomycin-resistant Enterococcus (VRE) bloodstream infection after an ERCP on June 12, 2023, performed with an Olympus TJF-Q190V duodenoscope. As Infection Control Today notes, Olympus has not been found liable in connection with those allegations. For background on how an earlier case turned out, see what the 2017 Seattle verdict decided.
The FDA
- Warning letter. The FDA’s October 7, 2026 letter cites quality-system violations at six Olympus facilities. It does not discuss the duodenoscope infection claims. Our explainer is here.
- Import alert. On October 19 and 20, the FDA added five models to its import alert on Olympus devices made in Japan. The FDA’s published table now lists 63 models, covering bronchoscopes, ureterorenoscopes, laparoscopes, enteroscopes, capsule imaging systems and automated endoscope reprocessors. No duodenoscope appears in it. Our explainer is here.
- Since then. The FDA’s page on the import alert still shows October 20 as its current date, and our check this week turned up no new FDA announcement about Olympus.
Olympus
Olympus announced the warning letter on October 13 and said it would submit a comprehensive response within 15 business days of receipt and supplement it with periodic updates until the FDA determines its actions are adequate. We have not found a public copy of that response. In a notice on October 21, Olympus said it does not expect the import alerts to have an incremental effect on its consolidated financial results for the fiscal year ending March 31, 2027. Local reporting in mid-October said Olympus’s next earnings report was expected within a month.
What to watch next
- Any public version of Olympus’s response to the warning letter, or an FDA statement on whether it is adequate.
- New models added to, or removed from, the import alert.
- A request to consolidate the federal cases in an MDL.
- Olympus’s next earnings report and anything it says about the FDA.
If you or a family member developed a serious infection after an endoscopic procedure, a free, confidential case review can explain how these developments may or may not matter to your situation.
Frequently asked questions
Is there an MDL for Olympus scope infection lawsuits?
As of early November 2026, legal trackers that cite the Judicial Panel on Multidistrict Litigation’s docket report no pending petition to consolidate Olympus scope cases. We could not view the Panel’s current list ourselves, so check it directly for the latest.
Are the FDA’s October 2026 actions resolved?
No. The FDA said it continues to have concerns about outstanding Quality System regulation violations, and Olympus has said it will provide periodic updates until the FDA determines its actions are adequate.
Do the FDA actions involve duodenoscopes?
The warning letter concerns quality systems at six facilities and does not discuss the duodenoscope infection claims. The import alert’s published model list does not include duodenoscopes.
Sources
- FDA: Update: Import Alert for Certain Olympus Medical Devices Manufactured in Japan, Letter to Health Care Providers (October 20, 2026)
- FDA: Warning Letter to Olympus Medical Systems Corporation, CMS #729208 (October 7, 2026)
- Olympus: Olympus Receives FDA Warning Letter (October 13, 2026)
- Olympus: Notice Regarding Issuance of Import Alerts by FDA (October 21, 2026)
- Infection Control Today: Can Reusable Duodenoscopes Still Transmit Infections? New Olympus Lawsuit Alleges Fatal VRE Case
- WFMZ: Olympus acknowledges new Warning Letter from FDA (October 2026)
Facts in this article come from the sources listed above and were current when the article was published or last updated. Statements about lawsuits describe allegations, which are claims and not findings by a court.
This article is general information, not medical or legal advice. Reading it does not create an attorney-client relationship. If you have symptoms of an infection, contact your health care provider. Attorney advertising. Prior results do not guarantee a similar outcome.